Clinical Research Consultants | Kansas City, MO

Research site

(Unclaimed)

Location

3930 Washington Street, Kansas City, Missouri, United States of America

Site insights

Top conditions

Top treatments

Empagliflozin

Semaglutide

Bardoxolone Methyl

Finerenone

KRX-0502

LNP023

Ferric Citrate

RTA 901

GFB-887

PF-04634817

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 46 total trials

A Phase 2 Study of RTA 901 (BIIB143) in Participants With Diabetic Peripheral Neuropathic Pain (CYPRESS)

This is a 2-part, randomized, placebo-controlled, double-blind, Phase 2 study to evaluate the safety, tolerability, efficacy, and pharmacokinetics (P...

Enrolling

Diabetic Peripheral Neuropathic Pain

Drug: RTA 901

Drug: RTA 901-Matching Placebo

Locations recently updated

A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who h...

Enrolling

Primary IgA Nephropathy

Drug: LNP023

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

This study is open to adults who are at least 18 years old and have a body mass index (BMI)bof 27 kg/m2 or more. People can take part if they have ca...

Active, not recruiting

Obesity

Drug: Placebo

Drug: survodutide

Locations recently updated

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (FIND-CKD)

Researchers are looking for a better way to treat people who have non-diabetic chronic kidney disease (non-diabetic CKD). The trial treatment, finere...

Active, not recruiting

Non-diabetic Chronic Kidney Disease

Drug: Finerenone (BAY94-8862)

Drug: Placebo

REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vessels

This study will look at the effects of CagriSema on cardiovascular events (for example heart attack and stroke) in people living with cardiovascular...

Active, not recruiting

Cardiovascular Disease

Drug: Cagrilintide

Drug: Semaglutide

Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients (APPLAUSE-IgAN)

The study is designed as a multicenter, randomized, double-blind, placebo controlled study to demonstrate the superiority of iptacopan (LNP023) at a...

Active, not recruiting

IgA Nephropathy

Drug: Placebo

Drug: LNP023

Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients (Ta1)

Thymalfasin (thymosin alpha 1 or Ta1), the active pharmaceutical ingredient in ZADAXIN® injection, is a 28-amino acid synthetic peptide, identical to...

Active, not recruiting

COVID-19

Drug: Thymalfasin

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Active, not recruiting

Chronic Kidney Disease

Inflammation

Drug: Placebo (Ziltivekimab B)

Drug: Placebo (Ziltivekimab C)